کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2484273 | 1114305 | 2016 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
in vitro/in vivo correlations (IVIVC)Controlled release - انتشار کنترل شدهsite-specific absorption - جذب خاص سایتIntestinal absorption - جذب رودهPreclinical pharmacokinetics - فارماکوکینتیک پیشکلامیBioavailability - فراهم زیستیPhysiologically based pharmacokinetic modeling - مدلسازی فارماکوکینتیک مبتنی بر فیزیولوژی
موضوعات مرتبط
علوم پزشکی و سلامت
داروسازی، سم شناسی و علوم دارویی
اکتشاف دارویی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption](/preview/png/2484273.png)
چکیده انگلیسی
Given the complexity of controlled release (CR) formulations, selecting the right preclinical tools is important to enable decision making on the in vivo performance of these formulations during development. In recent years, with the advancements of absorption/physiologically based pharmacokinetic (PBPK) modeling, such computational approaches play an increasing role in guiding formulation development. Development of PBPK models for CR formulations requires additional information compared with immediate release (IR) products. Perhaps the most important aspect is the need to simulate absorption in the lower intestine. Relatively few publications have investigated the use of PBPK models for compounds with region-dependent absorption. In this manuscript, we use gaboxadol as a model compound with region-dependent absorption. We first explored gaboxadol regional absorption in dogs to develop a PBPK model for absorption in the large intestine. Two matrix-based CR formulations were subsequently developed and tested in minipigs and demonstrated distinctly different pharmacokinetic profiles from the IR formulation. A minipig absorption PBPK model successfully predicted the observed plasma concentration data, with the predictions based on the in vitro dissolution being within the observed experimental variability. Finally, we demonstrate the development of an in vitro-in vivo correlation for the preclinical data using the same PBPK model.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Pharmaceutical Sciences - Volume 105, Issue 2, February 2016, Pages 722-728
Journal: Journal of Pharmaceutical Sciences - Volume 105, Issue 2, February 2016, Pages 722-728
نویسندگان
Filippos Kesisoglou, Anand Balakrishnan, Kimberly Manser,